Shuo-hui Gao1, Chao Liu, Jun Wei, Ye Feng. 1. Department of General Surgery, the Third Hospital of Jilin University, Changchun, Jilin, China.
Abstract
BACKGROUND: Colon cancer is one of the major malignancies worldwide and it still remains resistant to much of the currently available chemotherapy. Downregulation of HGF/c-Met signaling pathway is an emerging therapy for cancer treatment. METHODS: In this study, the inhibitory effects of c-Met phosphorylation were observed with SU11274 on different colon cancer cell lines in vitro. RESULTS: The results revealed the significant inhibitory effects of SU11274 on cell proliferation and cell survival, in a time and dose-dependent manner. Furthermore, the inhibitory effects of SU11274 on different subgroups of colon cancer cells via the HGF/c-Met signaling pathway were implicated in this study. CONCLUSION: The results suggested the possible selective therapeutic effects of c-Met inhibitor on colon cancer.
BACKGROUND:Colon cancer is one of the major malignancies worldwide and it still remains resistant to much of the currently available chemotherapy. Downregulation of HGF/c-Met signaling pathway is an emerging therapy for cancer treatment. METHODS: In this study, the inhibitory effects of c-Met phosphorylation were observed with SU11274 on different colon cancer cell lines in vitro. RESULTS: The results revealed the significant inhibitory effects of SU11274 on cell proliferation and cell survival, in a time and dose-dependent manner. Furthermore, the inhibitory effects of SU11274 on different subgroups of colon cancer cells via the HGF/c-Met signaling pathway were implicated in this study. CONCLUSION: The results suggested the possible selective therapeutic effects of c-Met inhibitor on colon cancer.
Authors: Daniel Delitto; Eva Vertes-George; Steven J Hughes; Kevin E Behrns; Jose G Trevino Journal: World J Gastroenterol Date: 2014-07-14 Impact factor: 5.742